Tacelli Matteo, Lauri Gaetano, Tabacelia Daniela, Tieranu Cristian George, Arcidiacono Paolo Giorgio, Săftoiu Adrian
Pancreato-Biliary Endoscopy and Endosonography Division, Pancreas Translational & Clinical Research Center, San Raffaele Scientific Institute IRCCS, Vita-Salute San Raffaele University, Milan, Italy.
Pancreato-Biliary Endoscopy and Endosonography Division, Pancreas Translational & Clinical Research Center, San Raffaele Scientific Institute IRCCS, Vita-Salute San Raffaele University, Milan, Italy; "Vita-Salute" San Raffaele University, Milan, Italy.
Best Pract Res Clin Gastroenterol. 2025 Feb;74:101975. doi: 10.1016/j.bpg.2025.101975. Epub 2025 Jan 4.
The integration of Artificial Intelligence (AI) in endoscopic ultrasound (EUS) represents a transformative advancement in the early detection and management of biliopancreatic lesions. This review highlights the current state of AI-enhanced EUS (AI-EUS) for diagnosing solid and cystic pancreatic lesions, as well as biliary diseases. AI-driven models, including machine learning (ML) and deep learning (DL), have shown significant improvements in diagnostic accuracy, particularly in distinguishing pancreatic ductal adenocarcinoma (PDAC) from benign conditions and in the characterization of pancreatic cystic neoplasms. Advanced algorithms, such as convolutional neural networks (CNNs), enable precise image analysis, real-time lesion classification, and integration with clinical and genomic data for personalized care. In biliary diseases, AI-assisted systems enhance bile duct visualization and streamline diagnostic workflows, minimizing operator dependency. Emerging applications, such as AI-guided EUS fine-needle aspiration (FNA) and biopsy (FNB), improve diagnostic yields while reducing errors. Despite these advancements, challenges remain, including data standardization, model interpretability, and ethical concerns regarding data privacy. Future developments aim to integrate multimodal imaging, real-time procedural support, and predictive analytics to further refine the diagnostic and therapeutic potential of AI-EUS. AI-driven innovation in EUS stands poised to revolutionize pancreatico-biliary diagnostics, facilitating earlier detection, enhancing precision, and paving the way for personalized medicine in gastrointestinal oncology and beyond.
人工智能(AI)与内镜超声(EUS)的整合代表了胆胰病变早期检测和管理方面的变革性进展。本综述重点介绍了人工智能增强型内镜超声(AI-EUS)在诊断实性和囊性胰腺病变以及胆道疾病方面的现状。包括机器学习(ML)和深度学习(DL)在内的人工智能驱动模型在诊断准确性方面有显著提高,特别是在区分胰腺导管腺癌(PDAC)与良性疾病以及胰腺囊性肿瘤的特征描述方面。先进的算法,如卷积神经网络(CNN),能够进行精确的图像分析、实时病变分类,并与临床和基因组数据整合以实现个性化医疗。在胆道疾病中,人工智能辅助系统可增强胆管可视化并简化诊断工作流程,减少对操作者的依赖。新兴应用,如人工智能引导的内镜超声细针穿刺抽吸(FNA)和活检(FNB),可提高诊断率并减少误差。尽管取得了这些进展,但挑战依然存在,包括数据标准化、模型可解释性以及数据隐私方面的伦理问题。未来的发展旨在整合多模态成像、实时操作支持和预测分析,以进一步提升AI-EUS的诊断和治疗潜力。EUS领域的人工智能驱动创新有望彻底改变胰胆诊断,促进早期检测,提高精准度,并为胃肠肿瘤学及其他领域的个性化医疗铺平道路。